Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif. , June 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin (EFX), formerly known as AKR-001, in patients with n...
Akero Therapeutics ( AKRO +2.4% ) plans to announce additional efficacy and safety data, including biopsy results, from its Phase 2a BALANCED study of AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), on June 30 (after hours trading). More news on: Akero ...
SOUTH SAN FRANCISCO, Calif. , June 29, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss new efficacy and safety data, including biopsy results, from its Phase 2a BALANCED study of AKR-001 in patients with biopsy-confirmed nonal...
Akero Therapeutics ( AKRO +1.6% ) doses first subject in Cohort C, the expansion of its Phase 2a BALANCED trial , which will enroll 30 subjects who have non-alcoholic steatohepatitis (NASH) with compensated cirrhosis (F4), Child-Pugh Class A. More news on: Akero Therapeutics, Inc...
SOUTH SAN FRANCISCO, Calif. , June 17, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, ...
SOUTH SAN FRANCISCO, Calif. , June 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, ...
Plenty of promising biotech stocks on the market right now have slipped under the radar thanks to the COVID-19 pandemic. Akero Therapeutics (NASDAQ: AKRO) is one such company. Founded back in 2017 and only recently going public in mid-2019, Akero managed to attract a fair bit of excitement s...
Shares of TripAdvisor (NASDAQ: TRIP) were surging over 10% Monday morning as prospects for a reopened economy would have people traveling again, both in the U.S. and overseas. Stay-at-home orders in response to the coronavirus pandemic have crushed the travel and hospitality industries, but...
SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NAS...
Akero Therapeutics (NASDAQ: AKRO ): Q1 GAAP EPS of -$0.42 beats by $0.19 . More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NASDAQ Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...